Clinical trial
Study of XL999 in Adults With Solid Tumors
NCT00104117 · Symphony Evolution, Inc., Industry · Completed
Key facts
| NCT number | NCT00104117 |
|---|---|
| Title | Study of XL999 in Adults With Solid Tumors |
| Official title | A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Solid Tumors |
| Lead sponsor | Symphony Evolution, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | XL999 |
| Enrollment | 52 |
| Start date | Nov 1, 2004 |
| Primary completion | Sep 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Feb 24, 2005 |
| Last update posted | Feb 19, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: